Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9FT0A
|
|||
| Drug Name |
R552
|
|||
| Synonyms |
2-(Methylthio)thiazole; 5053-24-7; 2-Methylthiothiazole; 2-methylthio thiazole; 2-Methylthio-1,3-thiazole; Thiazole, 2-(methylthio)-; 2-methylsulfanyl-1,3-thiazole; 2-(methylsulfanyl)-1,3-thiazole; MFCD00858981; ACMC-209knn; 2-(methylthio) thiazole; 2-methylsulfanyl-thiazole; 2-(Methylmercapto)thiazole; 2-Methylthiothiazole, 97%; C4H5NS2; SCHEMBL496215; DTXSID60375024; ZINC2570798; ANW-31041; AKOS006223218; GS-6827; FT-0658231; M1712; A828155; Q-100565
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Nervous system paraneoplastic or autoimmune disorders [ICD-11: 8E4A.1] | Phase 1 | [1] | |
| Company |
Rigel
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C4H5NS2
|
|||
| Canonical SMILES |
CSC1=NC=CS1
|
|||
| InChI |
1S/C4H5NS2/c1-6-4-5-2-3-7-4/h2-3H,1H3
|
|||
| InChIKey |
VQNOAXZUEKPSJC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 5053-24-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Receptor-interacting protein 1 (RIPK1) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Rigel. | |||
| REF 2 | Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.